ESR1 L536R

CI-VAR-00002362Explore in graph →NP_000116.2:p.Leu536ArgNM_000125.3:c.1607T>GClinVar 375937 CIViC 1675

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
ESR1 L536R	Palbociclib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4811 In a phase 3 clinical trial (NCT01942135) of 360 premenopausal and postmenopausal women with advanced, hormone receptor-positive breast cancer who had progressed during prior endocrine therapy, patien… (full text at CIViC) PMID 27269946 · Fribbens et al., 2016 · Open in CIViC	civic
Estrogen Receptor-positive Breast Cancer1unmapped disease
ESR1 L536R	Elacestrant	Predictive	A	Supports Sensitivity Response	2	submitted	EID12228 In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.